Imunon, Inc. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Imunon, Inc. stock issued during period, value, new issues for the quarter ending 2026-06-30 was $842.70K, a 70.51% decline year-over-year.
- Imunon, Inc. stock issued during period, value, new issues for the quarter ending 2025-12-31 was $7.19M.
- Imunon, Inc. stock issued during period, value, new issues for the quarter ending 2025-09-30 was $3.47M, a 61.68% decline year-over-year.
- Imunon, Inc. stock issued during period, value, new issues for the quarter ending 2025-06-30 was $2.86M.
- Imunon, Inc. stock issued during period, value, new issues for fiscal 2025 was $13.63M, a 50.41% increase from fiscal 2024.
- Imunon, Inc. stock issued during period, value, new issues for fiscal 2024 was $9.06M, a 225.75% increase from fiscal 2023.
- Imunon, Inc. stock issued during period, value, new issues for fiscal 2023 was $2.78M, a 58.63% decline from fiscal 2022.
- Imunon, Inc. stock issued during period, value, new issues for fiscal 2022 was $6.72M, a 87.24% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2026-06-30 | $842.70K 10-Q · filed 2026-08-11 | |
| 2025-12-31 | $7.19M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $13.63M 10-K · filed 2026-03-31 |
| 2025-09-30 | $3.47M 10-Q · filed 2025-11-13 | $6.43M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $2.86M 10-Q · filed 2026-08-11 | $12.02M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $105.69K 10-Q · filed 2026-05-12 | |
| 2024-12-31 | -$3.28K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $9.06M 10-K · filed 2026-03-31 |
| 2024-09-30 | $9.06M 10-Q · filed 2024-11-07 | |
| 2023-12-31 | $30.78K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $2.78M 10-K · filed 2025-02-27 |
| 2023-09-30 | $77.73K 10-Q · filed 2024-11-07 | $3.20M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $198.56K 10-Q · filed 2024-08-14 | $3.06M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $2.47M 10-Q · filed 2024-05-13 | $9.20M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $447.31K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $6.72M 10-K · filed 2024-03-28 |
| 2022-09-30 | -$64.02K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | |
| 2022-06-30 | $6.34M 10-Q · filed 2023-08-10 | |
| 2021-12-31 | $1.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $52.69M 10-K · filed 2023-03-30 |
| 2021-09-30 | -$8.32K 10-Q · filed 2021-11-15 | $55.25M derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-06-30 | $13.75M 10-Q · filed 2022-08-15 | $57.33M derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | $38.94M 10-Q · filed 2022-05-16 | $55.96M derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | $2.56M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $22.81M 10-K · filed 2022-03-31 |
| 2020-09-30 | $2.07M 10-Q · filed 2021-11-15 | |
| 2020-06-30 | $12.39M 10-Q · filed 2021-08-12 | |
| 2020-03-31 | $5.79M 10-Q · filed 2021-05-14 | |
| 2017-12-31 | $17.91M 10-K · filed 2019-03-29 | |
| 2016-12-31 | $6.78M 10-K · filed 2018-03-27 | |
| 2013-12-31 | $18.22M 10-K · filed 2016-03-30 | |
| 2011-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2012-03-15 | $3.12M 10-K · filed 2012-03-15 |
| 2011-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-10 | |
| 2011-06-30 | $2.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2011-08-09 | |
| 2011-03-31 | $588.86K 10-Q · filed 2012-05-15 | |
| 2010-12-31 | $2.62M 10-K · filed 2012-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |